Q1 2026 Achieve Life Sciences Inc Earnings Call Transcript
Key Points
- Achieve Life Sciences Inc (ACHV) closed a transformational financing deal, securing $180 million in upfront capital and up to $174 million from milestone-based warrants.
- The company has partnered with US-based Adare Pharma Solutions to manufacture cytisinicline, reducing risks related to international importation.
- Clinical data shows cytisinicline's potential efficacy in smoking cessation, with a favorable tolerability profile and low nausea rates.
- New Board members and commercial team leaders with significant industry experience have been appointed, strengthening the company's leadership.
- Achieve Life Sciences Inc (ACHV) has a strong capital position to execute its strategy for approval and launch, with a US-based supply chain to support manufacturing and launch timing.
- The company expects to receive a complete response letter from the FDA due to issues with a third-party manufacturer, delaying the NDA resubmission to the fourth quarter of 2026.
- There is uncertainty regarding the timeline for the commercial launch, which is now expected in the first half of 2027.
- The transition to a new manufacturing partner, Adare Pharma Solutions, involves completing a tech transfer and ensuring readiness, which could pose challenges.
- Achieve Life Sciences Inc (ACHV) faces competition from other smoking cessation aids and therapies, which could impact market positioning.
- The company is constrained in its communication about cytisinicline in a pre-approval environment, which may affect awareness and education efforts.
Greetings, and welcome to the Achieve Life Sciences first quarter 2026 earnings conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the call over to Nicole Jones, Achieve's Vice President, Strategic Communications and Stakeholder Relations. You may begin.
Thank you, operator. Good morning, everyone, and thank you for joining us today. From Achieve Life Sciences, we are joined by Dr. Andrew Goldberg, Chief Executive Officer, who will deliver the prepared remarks. Joining Dr. Goldberg for the Q&A will be Mark Oki, Chief Financial Officer. A replay will be available later today using the information in the earnings press release or by visiting the Achieve Life Sciences website.
Today's conference call will contain certain forward-looking statements, including statements regarding the goals, strategies, beliefs, expectations and future potential operating results of Achieve.
Although management
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
